IDEXX Laboratories, Inc. (IDXX)
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates
Idexx Laboratories (IDXX) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.40 per share. This compares to earnings of $2.32 per share a year ago.
Animal diagnostics maker IDEXX beats quarterly estimates despite low vet visits
IDEXX Laboratories beat Wall Street estimates for fourth-quarter revenue and profit on Monday, helped by strong demand for its veterinary diagnostic services despite persistent weakness in visits to the vet clinic.
IDXX Gears Up for Q4 Earnings: What to Expect From the Stock?
IDEXX Laboratories' fourth-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.
IDXX Stock Set to Benefit From IDEXX Cancer Dx Diagnostic Panel Launch
IDEXX launches new cancer Dx Panel with early detection test for canine lymphoma.
IDEXX Stock Suffers Due to Macroeconomic Issues and FX Woes
With sustained inflationary pressure, IDEXX may struggle to keep its cost of revenues and operating expenses in check.
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
A Once-in-a-Decade Opportunity: 2 Magnificent S&P 500 Stocks Down 37% and 28% to Buy Before 2025
One of my favorite ways to add money to my portfolio is to invest in proven compounders with track records of delivering market-beating results after short-term pullbacks. This idea is especially true when the stocks in question are trading at what could prove to be once-in-a-decade opportunities.
Should You Hold IDEXX Stock in Your Portfolio for Now?
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
IDEXX Laboratories Q3: Weak End-Market Demand Continues
I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits and missed market expectations, leading to lowered revenue growth guidance for FY24. Despite strong recurring revenue growth and high retention rates, ongoing macroeconomic challenges and high-interest rates are expected to impact IDEXX's business growth.
A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback
Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today.
IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Transcript
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Jonathan Block - Stifel Erin Wright - Morgan Stanley Brandon Vasquez - William Blair David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Third Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded.
Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth
Idexx Laboratories Inc IDXX reported third-quarter adjusted EPS of $2.79, up 12% year-over-year, beating the consensus of $2.68.
